Adverse events associated with apheresis procedures: Incidence and relative frequency

Introduction: Apheresis procedures [Plateletpheresis, Plasmapheresis/ Therapeutic Plasma Exchange (TPE), & Peripheral Blood Stem Cell Collection (PBSC)] are usually well tolerated. Occasionally, Adverse Events (AEs) of variable severity may occur during or after the procedure. AEs that occur in...

Full description

Bibliographic Details
Main Authors: Joseph Philip, Ravi S Sarkar, Amardeep Pathak
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Asian Journal of Transfusion Science
Subjects:
Online Access:http://www.ajts.org/article.asp?issn=0973-6247;year=2013;volume=7;issue=1;spage=37;epage=41;aulast=Philip
id doaj-edadc8983fd7405489d570f7b05f6c83
record_format Article
spelling doaj-edadc8983fd7405489d570f7b05f6c832020-11-25T00:32:42ZengWolters Kluwer Medknow PublicationsAsian Journal of Transfusion Science0973-62471998-35652013-01-0171374110.4103/0973-6247.106730Adverse events associated with apheresis procedures: Incidence and relative frequencyJoseph PhilipRavi S SarkarAmardeep PathakIntroduction: Apheresis procedures [Plateletpheresis, Plasmapheresis/ Therapeutic Plasma Exchange (TPE), & Peripheral Blood Stem Cell Collection (PBSC)] are usually well tolerated. Occasionally, Adverse Events (AEs) of variable severity may occur during or after the procedure. AEs that occur in Donors/Patients are divided into local reactions and systemic reactions. Materials and Methods: A total of 3,367 apheresis procedures were performed, out of which 3,120 were plateletpheresis procedures, and out of which 1,401 were on Baxter CS 3000 & 1,719 were on Haemonetics MCS+ cell separators. Rest of 247 TPE & PBSC procedures were done on Haemonetics MCS+ cell separators. Results: 90 AEs were reported in relation to the 3,367 procedures. Out of 90 AEs, 85 AEs (94%) were associated with plateletpheresis (n = 3,120) and 05 AEs (06%) with TPE & PBSC (n = 247). The rate of vascular injury (VI), Citrate reaction (CR), and Presyncopal/Syncopal (PS/S) in plateletpheresis was 1.6% (52/3,120), 0.96% (30/3,120), and 0.096% (03/3,120), respectively. The rate of CR in TPE and PBSC was 1.23% (02/162) and 2.3% (02/85), respectively. The rate of PS/S in PBSC was 1.17% (01/85). AEs for Plateletpheresis, TPE & PBSC were 2.7% (85/3,120), 1.23% (02/162), and 3.5% (03/85), respectively. VI, CR, and PS/S were mostly of mild intensity. Both cell separators were equally safe, when AEs associated with plateletpheresis were compared with each other; 2.8% on CS 3000 & 2.6% on MCS+. Conclusion: Apheresis procedures performed on cell separators are safe, with a low incidence of significant AEs. No significant difference was noted in AEs among the two cell separators studied.http://www.ajts.org/article.asp?issn=0973-6247;year=2013;volume=7;issue=1;spage=37;epage=41;aulast=PhilipAdverse eventscitrate reactionperipheral blood stem cellpresyncopal/syncopaltherapeutic plasma exchangevascular injury
collection DOAJ
language English
format Article
sources DOAJ
author Joseph Philip
Ravi S Sarkar
Amardeep Pathak
spellingShingle Joseph Philip
Ravi S Sarkar
Amardeep Pathak
Adverse events associated with apheresis procedures: Incidence and relative frequency
Asian Journal of Transfusion Science
Adverse events
citrate reaction
peripheral blood stem cell
presyncopal/syncopal
therapeutic plasma exchange
vascular injury
author_facet Joseph Philip
Ravi S Sarkar
Amardeep Pathak
author_sort Joseph Philip
title Adverse events associated with apheresis procedures: Incidence and relative frequency
title_short Adverse events associated with apheresis procedures: Incidence and relative frequency
title_full Adverse events associated with apheresis procedures: Incidence and relative frequency
title_fullStr Adverse events associated with apheresis procedures: Incidence and relative frequency
title_full_unstemmed Adverse events associated with apheresis procedures: Incidence and relative frequency
title_sort adverse events associated with apheresis procedures: incidence and relative frequency
publisher Wolters Kluwer Medknow Publications
series Asian Journal of Transfusion Science
issn 0973-6247
1998-3565
publishDate 2013-01-01
description Introduction: Apheresis procedures [Plateletpheresis, Plasmapheresis/ Therapeutic Plasma Exchange (TPE), & Peripheral Blood Stem Cell Collection (PBSC)] are usually well tolerated. Occasionally, Adverse Events (AEs) of variable severity may occur during or after the procedure. AEs that occur in Donors/Patients are divided into local reactions and systemic reactions. Materials and Methods: A total of 3,367 apheresis procedures were performed, out of which 3,120 were plateletpheresis procedures, and out of which 1,401 were on Baxter CS 3000 & 1,719 were on Haemonetics MCS+ cell separators. Rest of 247 TPE & PBSC procedures were done on Haemonetics MCS+ cell separators. Results: 90 AEs were reported in relation to the 3,367 procedures. Out of 90 AEs, 85 AEs (94%) were associated with plateletpheresis (n = 3,120) and 05 AEs (06%) with TPE & PBSC (n = 247). The rate of vascular injury (VI), Citrate reaction (CR), and Presyncopal/Syncopal (PS/S) in plateletpheresis was 1.6% (52/3,120), 0.96% (30/3,120), and 0.096% (03/3,120), respectively. The rate of CR in TPE and PBSC was 1.23% (02/162) and 2.3% (02/85), respectively. The rate of PS/S in PBSC was 1.17% (01/85). AEs for Plateletpheresis, TPE & PBSC were 2.7% (85/3,120), 1.23% (02/162), and 3.5% (03/85), respectively. VI, CR, and PS/S were mostly of mild intensity. Both cell separators were equally safe, when AEs associated with plateletpheresis were compared with each other; 2.8% on CS 3000 & 2.6% on MCS+. Conclusion: Apheresis procedures performed on cell separators are safe, with a low incidence of significant AEs. No significant difference was noted in AEs among the two cell separators studied.
topic Adverse events
citrate reaction
peripheral blood stem cell
presyncopal/syncopal
therapeutic plasma exchange
vascular injury
url http://www.ajts.org/article.asp?issn=0973-6247;year=2013;volume=7;issue=1;spage=37;epage=41;aulast=Philip
work_keys_str_mv AT josephphilip adverseeventsassociatedwithapheresisproceduresincidenceandrelativefrequency
AT ravissarkar adverseeventsassociatedwithapheresisproceduresincidenceandrelativefrequency
AT amardeeppathak adverseeventsassociatedwithapheresisproceduresincidenceandrelativefrequency
_version_ 1725319540704804864